Abstract | PURPOSE: METHODS:
CPX-351 PK data ( cytarabine, daunorubicin, and metabolites) from a phase I study of relapsed and refractory AML were used for the analysis. Therapy was given days 1, 3, and 5 of induction (3-134 units/m2). We developed a population PK model to characterize CPX-351 disposition. RESULTS: 39 patients (3589 samples) were evaluated. Liposomal cytarabine and daunorubicin were modeled separately with their respective metabolites. A one-compartment model fit the parent compounds well; the metabolites required two-compartment models. Weight was an independent predictor of liposomal volumes; mild renal and liver dysfunction were not predictors of clearance or volume (maximum creatinine 1.6 mg/dL and total bilirubin 1.8 mg/dL). Liposomal clearances of the two drugs were highly correlated and 1000-fold smaller than published non-encapsulated values supporting prolonged encapsulation in the liposome. CONCLUSIONS: The PK model demonstrates prolonged exposure to cytarabine and daunorubicin without increases in non-hematologic toxicity that indicates retention of the drugs within the liposome. The unique pharmacology of this formulation may allow for simplified regimens and improved outcomes.
|
Authors | Mina Nikanjam, Edmund V Capparelli, Jeffrey E Lancet, Arthur Louie, Gary Schiller |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 81
Issue 1
Pg. 171-178
(01 2018)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 29167924
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- CPX-351
- Liposomes
- Cytarabine
- Daunorubicin
|
Topics |
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, pharmacokinetics)
- Area Under Curve
- Cytarabine
(administration & dosage, pharmacokinetics)
- Daunorubicin
(administration & dosage, pharmacokinetics)
- Female
- Humans
- Leukemia, Myeloid, Acute
(drug therapy)
- Liposomes
- Male
|